Online training STRIDE II guidelines in inflammatory bowel disease – A case-based discussion. Gastroenterology and Hepatology Partner Content RX Training with partner View Post
View Post This content is machine translated Sponsored Content: UEGW update: Post-hoc analyses of the SEQUENCE study Risankizumab is convincing compared to ustekinumab [1] The SEQUENCE comparative study recently published in the New England Journal of Medicine (NEJM) compared the two interleukin (IL)-23 and IL-12/-23 inhibitors risankizumab (SKYRIZI®) and ustekinumab in Crohn’s disease (CD) patients [1-3]. Supplementary post-hoc analyses have now been presented at this year’s United European Gastroenterology Week (UEGW) from October 12 to 15, 2024 in Vienna [4-6]. The results show, among other things, that risankizumab achieves numerically higher efficacy rates compared to ustekinumab regardless of disease duration, leads to greater normalization of biomarkers and significantly improves quality of life [4-6]. View Post
View Post This content is machine translated Sponsored Content: Crohn's disease Biomarkers underline superiority of risankizumab compared to ustekinumab in Crohn’s disease [1] In the SEQUENCE study, risankizumab was compared with ustekinumab for the treatment of Crohn’s disease (CD) in patients who had failed anti-TNF therapies. Biomarkers such as fecal calprotectin (FC) and C-reactive protein (CRP) were also measured [1]. In addition to the clinical and endoscopic endpoints, these biomarkers made it possible to objectively assess the course of the disease [1]. View Post
View Post This content is machine translated Sponsored Content: United European Gastroenterology Week (UEGW) 2023 Risankizumab demonstrates superiority compared to ustekinumab in Crohn’s disease [1] Data from the current SEQUENCE study was presented at the United European Gastroenterology Week (UEGW), which took place from October 14 to 17, 2023, and has since been published [1,2]. In der randomisierten Phase-III-Head-to-Head-Studie wurde Risankizumab (SKYRIZI®) mit Ustekinumab zur Behandlung erwachsener Patient:innen mit mittelschwerem bis schwerem aktivem Morbus Crohn (CD, Crohn’s Disease) verglichen, bei denen eine oder mehrere Anti-TNF-Therapien versagt hatten [1]. Risankizumab achieved all primary and secondary endpoints compared to ustekinumab and demonstrated superiority [1]. SEQUENCE is therefore the only head-to-head study in Crohn’s disease to show superiority of a biologic over another biologic. View Post
View Post This content is machine translated 11th Swiss IBD Roadshow “Curing mucosa is our major goal” The meanwhile 11th Swiss IBD Roadshow (10. – 12. June 2024) took place this year under the title “ADVANCED THERAPIES IN IBD – TOWARDS A NEW SEQUENCE”. Between his lectures in seven Swiss centers, Prof. Laurent Peyrin-Biroulet from Nancy University Hospital, France, shared his experiences and thoughts on advanced therapies and treatment procedures in inflammatory bowel disease (IBD). He highlighted the effectiveness of recent additions to the treatment landscape and called for a closer analysis of the risk-benefit profile of available therapies. View Post
View Post This content is machine translated A case-based discussion Optimization of perioperative care in IBD. The perioperative care of IBD patients is crucial for optimizing the treatment outcome. Close contact with the surgeon and the joint assessment, care and treatment of patients enable customized medical and nutritional therapy with the best results. In this way, the increased morbidity and six-fold increase in mortality associated with emergency surgery for IBD patients can be avoided. CME-Test View Post
View Post This content is machine translated 10th Swiss IBD Roadshow – anniversary edition “With IBD, the biggest risk is often not treating those affected” Following the conclusion of the 10th Swiss IBD Roadshow, which took place in eight Swiss centers from June 5-7, 2023, Prof. James Lindsay from Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK, shares his experiences and thoughts on patient care, diagnostics and modern therapy for inflammatory bowel disease (IBD). He highlights the key similarities and differences between the United Kingdom (UK) and Switzerland and points out areas where clinicians and caregivers in both countries can learn from each other. View Post
View Post This content is machine translated Chronic inflammatory bowel disease Webinar: IBD Update by AbbVie Inflammatory bowel diseases (IBD) are complex diseases that affect the lives of millions of people worldwide. In the webinar of the IBD Update by AbbVie series on October 5, 2023, interdisciplinary and highly qualified speakers from gastroenterology and dermatology will discuss new treatment options and share experiences in everyday clinical practice. View Post
View Post This content is machine translated ONLINE TRAINING Optimization of perioperative care in IBD. In this case-based discussion, Prof. Michel Adamina, MD, Chief of the Clinic for Visceral and Thoracic Surgery at the Winterthur Cantonal Hospital, PD Pascal Juillerat, MD, a specialist in gastroenterology and hepatology at the Centre Crohn et colite in Lausanne, and Maude Martinho-Grüber, MD, a specialist in gastroenterology at the Clinique de la Source in Lausanne, provide an overview of optimizing perioperative care in IBD. CME-Test View Post
View Post This content is machine translated Inflammatory Bowel Disease (IBD) STRIDE II Guideline Recommendations The STRIDE II supplement includes evidence- and consensus-based recommendations for targeted treatment strategies in adults and children with IBD. Confirmed that the most important long-term achievable treatment goals for patients are clinical remission, endoscopic cure, restoration of quality of life, and absence of disability. CME-Test View Post
View Post This content is machine translated 8th IBDnet Postgraduate Course Inflammatory bowel disease – Are my treatment goals worth it? The therapeutic landscape for inflammatory bowel disease (IBD) has expanded greatly in recent years. As a result, increasingly ambitious therapeutic goals are becoming realistic [1]. But is it worth steadily tightening them up and what are the potential risks involved? Prof. Raja Atreya explored these questions at the IBDnet Postgraduate Course. View Post
